Zielbio Begins Patient Dosing In Phase 1/2 Trial Of Zb131 In Patients With Solid Tumours
Zielbio, Inc., A Clinical Stage Biotechnology Company, Announced The First Patient Dosed In Its Phase 1/2 Clinical Trial. The Study Will Evaluate Zb131 In Patients With Solid Tumours Who Are Either Non-Responsive To Or Ineligible For The Standard Of Care.Zb131 Is A Monoclonal Antibody With A High Affinity And Specificity For Cancer Specific Plectin (Csp), A Cell Surface Protein Identified In A Wide Range Of Cancers That Correlates With Poor Prognosis And Aggressive Tumours.
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!